Saltar al contenido principal
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Observacional500 participantes buscados21 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Afecciones

  • Limbal Stem Cell Deficiency

Elegibilidad

Elegibilidad
SexoTodos
Edades12 Years – 99 Years
Voluntarios sanosNo
Método de muestreoPROBABILITY_SAMPLE

Población del estudio

Adult and adolescent subjects with qualifying LSCD

Elegibilidad tal como figura en el registro

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioObservacional
FaseNo indicado en el registro
AsignaciónNo indicado en el registro
Modelo de intervenciónNo indicado en el registro
Propósito principalNo indicado en el registro
EnmascaramientoNo indicado en el registro
Inscripción500 participantes buscados

Patrocinador y colaboradores

  • Claris Biotherapeutics, Inc. Patrocinador

Grupos e intervenciones

  • Non-interventional

    No product administration.

Intervenciones

  • Otro Non-interventional

    Non-interventional

Variables de resultado

  1. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Plazo Screening through Week 84

  2. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Plazo Screening through Week 84

  3. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Plazo Screening through Week 84

  4. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Plazo Screening through Week 84

  5. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Plazo Screening through Week 84

  6. Variable de resultado principal

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Plazo Screening through Week 84

  7. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Plazo Screening through Week 84

  8. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Plazo Screening through Week 84

  9. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Plazo Screening through Week 84

  10. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Plazo Screening through Week 84

  11. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Plazo Screening through Week 84

  12. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Plazo Screening through Week 84

  13. Variable de resultado secundaria

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Plazo Screening through Week 84

Fechas

Fechas
Fecha de inicio22 de mayo de 2026 (real)
Finalización principal1 de marzo de 2028 (estimada)
Finalización1 de marzo de 2028 (estimada)
Primera publicación9 de junio de 2026 (real)
Última actualización18 de noviembre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última veznoviembre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

21 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Claris Investigative SiteCarmelIndianaEn reclutamiento
Claris Investigative SiteCranberry TownshipPennsylvaniaEn reclutamiento
Claris Investigative SiteDraperUtahEn reclutamiento
Claris Investigative SiteHuntington BeachCaliforniaEn reclutamiento
Claris Investigative SiteIndianapolisIndianaEn reclutamiento
Claris Investigative SiteKansas CityMissouriEn reclutamiento
Claris Investigative SiteLa JollaCaliforniaEn reclutamiento
Claris Investigative SiteLos AngelesCaliforniaEn reclutamiento
Claris Investigative SiteLouisvilleKentuckyEn reclutamiento
Claris Investigative SiteMinnetonkaMinnesotaEn reclutamiento
Claris Investigative SiteNorfolkVirginiaEn reclutamiento
Claris Investigative SiteOverland ParkKansasEn reclutamiento
Claris Investigative SitePalisades ParkNew JerseyEn reclutamiento
Claris Investigative SitePortlandOregonEn reclutamiento
Claris Investigative SiteRockville CentreNew YorkEn reclutamiento
Claris Investigative SiteSan AntonioTexasEn reclutamiento
Claris Investigative SiteSioux FallsSouth DakotaEn reclutamiento
Claris Investigative SiteSmyrnaTennesseeEn reclutamiento
Claris Investigative SiteSouth DartmouthMassachusettsEn reclutamiento
Claris Investigative SiteTampaFloridaEn reclutamiento
Claris Investigative SiteWichitaKansasEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 18 de noviembre de 2026

    Centro añadido

    13 sites added (21 total)

    821

  2. 6 de agosto de 2026

    Centro añadido

    6 sites added (8 total)

    28